Protective effects of parecoxib, a cyclo-oxygenase-2 inhibitor, in postinfarction remodeling in the rat

Journal of Cardiovascular Pharmacology

Volumn 50, Issue 5, 2007, Pages 571-577

  Straino, Stefania ^a,b   Salloum, Fadi N ^a   Baldi, Alfonso ^c   Ockaili, Ramzi A ^a   Piro, Maddalena ^d   Das, Anindita ^a   Qureshi, Ian Z ^a   Biasucci, Luigi M ^d   Capogrossi, Maurizio C ^b   Biondi Zoccai, Giuseppe G L ^e   Severino, Anna ^d   Mellone, Pasquale ^c   Crea, Filippo ^d   Vetrovec, George W ^a   Kukreja, Rakesh C ^a   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

Acute myocardial infarction; Cyclo oxygenase 2; Heart failure; Ischemia

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; PARECOXIB; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY DIAMETER; ARTERY LIGATION; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY; DATA ANALYSIS; DIASTOLE; DRUG EFFECT; HEART INFARCTION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE REMODELING; HISTOLOGY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLE; TRANSTHORACIC ECHOCARDIOGRAPHY; VASCULARIZATION; WISTAR RAT;

ANIMALS; APOPTOSIS; ARTERIOLES; CYCLOOXYGENASE 2 INHIBITORS; CYTOKINES; ECHOCARDIOGRAPHY; HEART; ISOXAZOLES; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; VENTRICULAR REMODELING;

EID: 36349001707     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31814b91cb     Document Type: Article

References (18)

1. Abbate A, Bussani R, Amin MS, et al. Acute myocardial infarction and heart failure: role of apoptosis. Int J Biochem Cell Biol. 2006;38:1834-1840.
2. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4-15.
3. LaPointe MC, Mendez M, Leung A, et al. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol. 2004;286:H1416-H1424.
4. Saito T, Rodger IW, Hu F, et al. Inhibition of COX pathway in experimental myocardial infarction. J Mol Cell Cardiol. 2004:37:71-77.
5. Abbate A, Limana F, Capogrossi MC, et al. Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction. Apoptosis. 2006;11:1061-1063.
6. Timmers L, Sluijter JPG, Verlaan CWJ, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling and impairs systolic function after myocardial infarction in the pig. Circulation. 2007;115:326-332.
7. Shinmura K, Xuan YT, Tang XL, et al. Inducible nitric oxyde synthase modulates cyclo-oxygenase-2 activity in the heart of conscious rabbits during the late phase of ischemic preconditioning. Circ Res. 2002;90:602-608.
8. Abbate A, Santini D, Biondi-Zoccai GGL, et al. Cyclooxygenase-2 (COX-2) expression at site of recent myocardial infarction: friend or foe? Heart. 2004;90:440-443.
9. Telliez A, Furman C, Pommery N, et al. Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activities. Anticancer Agents Med Chem. 2006;6:187-208.
10. Abbate A, Bussani R, Biondi-Zoccai GGL, et al. Infarct-related artery occlusion, tissue markers of ischaemia, and increased apoptosis in the peri-infarct viable myocardium. Eur Heart J. 2005;26:2039-2045.
11. Straino S, Germani A, Di Carlo A, et al. Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation. 2004;110:3341-3348.
12. Abbate A, Biondi-Zoccai GGL, Leone AM, et al. Cyclooxygenase-2 in myocardial ischemia: is it really a friend? J Am Coll Cardiol. 2003;42:1714.
13. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-1091.
14. Patrono C. The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol. 2006;47:S1-S6.
15. Abbate A, Salloum FN, Ockaili RA, et al. Improvement of cardiac function with parecoxib, a cyclo-oxygenase-2 inhibitor, in rat model of ischemic heart failure. J Cardiovasc Pharmacol. 2007;49:416-418.
16. Zhang Z, Vezza R, Plappert T, et al. COX-2 dependent cardiac failure in Gh/tTG transgenic mice. Circ Res. 2003;92:1153-1161.
17. Takadera T, Yumoto H, Tozuka Y, et al. Prostaglandin E(2) induces caspase-dependent apoptosis in rat cortical cells. Neurosci Lett. 2002;317:61-64.
18. Judgutt BI. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation. 2007;115:288-291.